Login / Signup

Development of a Series of Pyrrolopyridone MAT2A Inhibitors.

Stephen J AtkinsonSharan K BagalArgyrides ArgyrouSean AskinTony CheungElisabetta ChiarparinMuireann CoenIain T CollieIan L DaleClaudia De FuscoKeith DillmanLaura EvansLyman J FeronAlison J FosterMichael GrondineVasudev KantaeGillian M LamontScott LamontJames T LynchSten Nilsson LillGraeme R RobbJamal SaehMarianne SchimplJames S ScottJames M SmithBharath SrinivasanSharon TentarelliMercedes Vazquez-ChantadaDavid J WagnerJarrod J WalshDavid WatsonBeth Williamson
Published in: Journal of medicinal chemistry (2024)
The optimization of an allosteric fragment, discovered by differential scanning fluorimetry, to an in vivo MAT2a tool inhibitor is discussed. The structure-based drug discovery approach, aided by relative binding free energy calculations, resulted in AZ'9567 ( 21 ), a potent inhibitor in vitro with excellent preclinical pharmacokinetic properties. This tool showed a selective antiproliferative effect on methylthioadenosine phosphorylase (MTAP) KO cells, both in vitro and in vivo, providing further evidence to support the utility of MAT2a inhibitors as potential anticancer therapies for MTAP-deficient tumors.
Keyphrases